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Abstract
Background: Health-workers in developing countries rely on clinical algorithms, such as the Integrated
Management of Childhood Illnesses (IMCI), for the management of patients, including diagnosis of serious bacterial
infections (SBI). The diagnostic accuracy of IMCI in detecting children with SBI is unknown. Prediction rules and
guidelines for SBI from well-resourced countries at outpatient level may help to improve current guidelines;
however, their diagnostic performance has not been evaluated in resource-limited countries, where clinical
conditions, access to care, and diagnostic capacity differ. The aim of this study was to estimate the diagnostic
accuracy of existing prediction rules and clinical guidelines in identifying children with SBI in a cohort of febrile
children attending outpatient health facilities in Tanzania.
Methods: Structured literature review to identify available prediction rules and guidelines aimed at detecting SBI
and retrospective, external validation on a dataset containing 1005 febrile Tanzanian children with acute infections.
The reference standard, SBI, was established based on rigorous clinical and microbiological criteria.
Results: Four prediction rules and five guidelines, including IMCI, could be validated. All examined rules and
guidelines had insufficient diagnostic accuracy for ruling-in or ruling-out SBI with positive and negative likelihood
ratios ranging from 1.04–1.87 to 0.47–0.92, respectively. IMCI had a sensitivity of 36.7% (95% CI 29.4–44.6%) at a
specificity of 70.3% (67.1–73.4%). Rules that use a combination of clinical and laboratory testing had better
performance compared to rules and guidelines using only clinical and or laboratory elements.
Conclusions: Currently applied guidelines for managing children with febrile illness have insufficient diagnostic
accuracy in detecting children with SBI. Revised clinical algorithms including simple point-of-care tests with
improved accuracy for detecting SBI targeting in tropical resource-poor settings are needed. They should undergo
careful external validation against clinical outcome before implementation, given the inherent limitations of gold
standards for SBI.
Keywords: Clinical prediction rules, Serious bacterial infections, Childhood infections, External validation, Diagnostic
accuracy, IMCI
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Background
Acute febrile illnesses are the most common presenta-
tion of young children attending outpatient settings
worldwide [1]. Like in well-resourced settings, the ma-
jority of acute febrile illnesses are caused by viral patho-
gens requiring minimal supportive intervention; serious
bacterial infections (SBI) have become increasingly rare
with improving vaccination coverage and hygiene [2, 3].
However, the lack of adequate diagnostic tools makes it
difficult to differentiate these viral diseases from the
minority of children with SBI. Children with serious
bacterial infections (SBI) often present with non-specific
clinical signs and several concomitant symptoms [4].
Sub-standard management of children with infections has
resulted in persistent high mortality from common child-
hood infections [5] and high-volume over-prescription of
antibiotics [6].
Health workers rely on the World Health Organization
(WHO) Integrated Management of Childhood Illnesses
(IMCI) algorithm, which recommends presumptive
treatment based on clinical signs and symptoms (besides
the rapid diagnostic test for malaria that was introduced
in the 2014 version, [7]). The Integrated Community
Case Management guidelines (iCCM) is a simplified ver-
sion of IMCI, geared towards community health workers
[8, 9]. Due to the lack of available evidence when IMCI
was initially developed, the algorithm was based mainly
on expert opinion in addition to small derivation studies
[10]. Though IMCI and iCCM have been implemented
globally, their performance in detecting children with
SBI has not been validated to date using stringent micro-
biological methods, instead of expert clinical diagnosis
(and chest radiograph (CXR) in some studies) [11, 12].
Adherence to IMCI has been low. The reasons for non-
adherence to IMCI are numerous and complex [13, 14],
but one important aspect is the content: for example,
IMCI lacks guidance in key areas, e.g. for patients with
fever without clinical focus [7]. As a result, clinicians
over-prescribe antibiotics out of the fear of missing
patients with SBI [15]. Therefore, there is a need to im-
prove current management guidelines for the primary
care management of acute febrile illnesses, including evi-
dence from economically developed countries. Here, a
series of clinical and laboratory prediction rules and clin-
ical guidelines, with different degrees of validation, have
been designed for the management of febrile children in
the ambulatory setting [16–27]. There is a growing body
of evidence that the causes of acute non-malaria febrile
illnesses in children in low- and high resource settings
are in fact quite similar [2]: cosmopolitan viruses and
bacteria are the causative agent in the vast majority of
cases while tropical pathogens cause only a minority of
febrile episodes at the outpatient level. Clinical signs and
laboratory tests from such clinical prediction rules and
guidelines developed in well-resourced countries may
thus also be useful for detecting SBI in children in low-
resource settings. However, external validation to sup-
port their use in resource-poor settings is lacking. This
is especially important because of differences in clinical
presentations (e.g. malaria co-infection), the health care
system (e.g. access to care, the possibility of safety net-
ting, the level of training of primary care providers).
Methods
Aim
The aim of this study was to estimate the diagnostic
accuracy of existing prediction rules and clinical guide-
lines, including IMCI and iCCM, in identifying children
with SBI in a resource-poor setting.
Design
We performed an external, retrospective validation study
of existing prediction rules and guidelines on a dataset
collected prospectively in Tanzania that contains chil-
dren aged 2 months to 10 years with fever presenting to
outpatient care [2].
Participants/ setting
The study population comprised 1005 children from a
study on causes of fever in rural and urban Tanzania,
the ‘Tanzanian Fever Study’ [2]. Briefly, children aged 2
months to 10 years with fever (axillary temperature of
≥38 °C) were enrolled consecutively at two outpatient
clinics in 2008. Children with severe acute malnutrition
and/or those requiring immediate live-saving procedures
were excluded. This was partly for safety reasons, but
also because WHO recommends antibiotic treatment for
all febrile children with severe acute malnutrition as
these patients have a distinct immune response putting
them at high risk of SBI [7, 28]. All participants in the
dataset, including children with malaria infection, were
included into the validation exercise. We performed
sensitivity analyses to assess the influence of malaria co-
infection on the diagnostic performance (see below).
Outcome definition
The outcome, SBI, i.e. a bacterial infection requiring
antibiotic treatment, was defined as presence of one of
the following: bacteremia (positive blood culture for a
known pathogen), Salmonella typhi infection (positive
blood-or stool culture, or positive specific IgM rapid
diagnostic test), radiographic pneumonia, urinary tract
infection (positive urine dipstick and urine culture),
meningitis, bacterial gastroenteritis (positive stool
culture), significant skin/soft tissue infections and other
systemic bacterial infections not routinely detected by
blood culture (rickettsiosis, coxiellosis, and leptospir-
osis). Definitions were based on the methodology used
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in the ‘Tanzania Fever Study’: for each patient, the final
diagnosis (or diagnoses) was established with a com-
puter-generated algorithm based on pre-defined clinical
and microbiological criteria [2]. These criteria were de-
rived from international guidelines as well as systematic
reviews.
Clinical and laboratory assessment
Investigators used standardized case report forms to rec-
ord clinical findings, including 23 symptoms and their
respective duration, potential travel history and/or sick
contacts, known chronic conditions, and 49 clinical
signs. At the initial visit a systematic set of investigations
was performed according to predefined algorithm; mal-
aria testing was done for all children [2]. If a clinical or
laboratory diagnosis could not be made at the initial
visit, a follow-up visit was scheduled for day 7 that
included a full clinical and laboratory assessment for
patients with persistent symptoms. In all cases, blood
samples and pooled nasal and throat swabs were taken
for microbiologic testing (cultures and rapid tests) on
site and further serologic and molecular work-up in
Switzerland and the USA. A complete blood cell count,
including white blood cell count was done on site for all
children. C-reactive protein (CRP) and procalcitonin
(PCT) were performed retrospectively on stored samples
by ELISA as detailed elsewhere [29]. CXR were per-
formed in the subgroup of cases fulfilling the WHO
clinical definition of pneumonia [30]. The diagnosis of
radiological pneumonia was made in cases where CXR
showed ‘primary endpoint consolidation’ according to
WHO’s Pneumococcal Trialist Ad Hoc Committee
recommendations [31]. If the IMCI clinical criteria for a
suspected human immunodeficiency virus (HIV) infec-
tion were present, voluntary HIV testing was recom-
mended to the child’s guardian.
Selection of prediction rules and guidelines
All available prediction rules (laboratory and clinical) for
identifying any SBI in children in the outpatient settings
were identified through a structured literature review in
Medline and Embase as part of the development of a
novel disease management algorithm [32]. The search
strategy is detailed in the Additional file 1 of the publica-
tion. The search was modified based on previously pub-
lished systematic review and a European validation study
[16, 33]. Prediction rules and guidelines that target the
neonatal period, i.e. < 3 months, were excluded. We also
did not include prediction rules that primarily aim at
predicting death (such as the PEDIA [34], LODS [35],
and SICK [36] scores) or the need for referral to the
pediatric intensive care unit at in-patient level. Scores
aimed at identifying dehydration for patients with
gastroenteritis, or at detecting children with meningitis
(there were only 2 patients with meningitis) were also
not included. When variables of the dataset were not
entirely matching the variables of the original rule or
guideline, we identified proxies where possible
(Additional file 2: Table S1). When more than 20% of
the required variables were not recorded in the dataset
(systematically missing), the rule/guideline was not in-
cluded in the validation. This was based on the assump-
tion that missing systematically more than 20% of
predictor variables was not clinically sensible. Missing
data on variables used in the validation were not
imputed because the necessary missing-at-random
assumption was likely to be incorrect given that all data
was collected based on a predefined algorithm. We
report the number of observations available for analysis
of each prediction rule after application of the above
assumptions. Where rules generated sum scores, previ-
ously published cut-offs were applied.
Statistical analysis
We used the Standard for Reporting of Diagnostic
Accuracy (STARD) guidelines for study reporting [37].
The accuracy of the included prediction rules and guide-
lines was estimated retrospectively in the prospectively
collected ‘Tanzania Fever Study’ dataset by calculating
sensitivity, specificity, and likelihood ratio (LR). For the
low prevalence outpatient setting we considered a score
helpful to rule-in SBI if, when positive, they substantially
raised the probability of SBI (LR+ greater 5). Scores were
deemed helpful for ruling-out SBI if, when negative, they
substantially lowered the probability of illness (LR- lower
than 0.2).
Clinical features were deemed warning signs if, when
positive, they substantially raised the probability of ill-
ness—i.e., positive likelihood ratio of more than 5.0.
Clinical features were deemed rule-out signs if, when
negative, they substantially lowered the probability of ill-
ness—i.e., negative likelihood ratio of less than 0.2.
We performed the following sensitivity analyses by
comparing the 95% confidence intervals (CIs) of diag-
nostic accuracy measures: First, to assess the influence
of age range, we compared the target age group of the
rules/ guidelines with those of the entire validation data-
set. Second, as some predictors (fast breathing in IMCI,
iCCM, and ALMANACH, and a positive CXR in the
American Academy of Emergency Physicians [AAEP]
guideline) were part of the diagnostic criteria for pneu-
monia in the validation dataset, we compared the full
dataset with a dataset excluding pneumonia cases for
these 4 guidelines. The same was done for UTI for pre-
diction scales and guidelines that use urinary dipstick
(Bleeker Score, Lab Score, ALMANACH and AAEP).
Third, since malaria is known to raise CRP values [38],
we compared malaria negative patients with the full
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dataset for prediction rules that contain CRP. Fourth, for
prediction rules that were originally derived for children
with fever without source, we compared the full dataset
with the dataset containing children with fever without
source only. All analyses were performed with Stata version
13.1. The confidence intervals were calculated using the
Stata diagt procedure (http://www.stata.com/stb/stb59/
sbe36_1/diagt.hlp. We used a web-based tool to generate
Venn diagrams (http://jura.wi.mit.edu/bioc/tools/venn.php).
Results
Prediction rules and guidelines
Through the structured literature review [32], we identi-
fied 34 prediction rules/guidelines for the use in febrile
children. Sixteen were designed to predict SBI at the
outpatient level (Fig. 1, Tables 1 and 2).
The NICE guideline is intended to predict ‘serious
disease’ among children with acute febrile illness, and
not to indicate antibiotic treatment. However, given that
it was the only guideline designed for the use by health-
care professionals in primary care with various levels of
training, we decided to include it in the validation exer-
cise. In addition to the prediction rules and guidelines
from the systematic review and European validation
study [16, 33], we found one additional prediction rule
for diagnosis of SBI [21], two prediction rules for pneu-
monia [24, 25], and four clinical guidelines (AAEP,
IMCI, iCCM, and ALMANACH [7, 8, 27, 41]). ALMA-
NACH is an improved IMCI-based algorithm that
includes urinary dipstick testing [9]. Additional file 2:
Table S1 displays whether the prediction rules and
guidelines could be used for retrospective validation, as
well as proxies for certain predictor variables used. For the
prediction rules, validation was possible for the Bleeker
Score, Thayyil Score, Lab Score and the Rotterdam Fever
Model. More than 20% of predictors were missing system-
atically for other prediction rules, including 3 pneumonia
rules. All clinical guidelines identified could be used for
Fig. 1 Flowchart of scores identified and considered for validation (adapted from [32]). Pediatric intensive care unit (PICU)
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Table 2 Guidelines for management of acute febrile illnesses in childrena
Name of
guideline
Age
Group
Clinical and laboratory features Publication
IMCI 2 m-5y CNS Hydration/ nutrition Respiratory Other
Danger signs - Lethargic or unconscious
-h/o convulsions or currently seizing
-stiff neck
- Vomits everything
-Unable to drink/ breastfeed
-Severe malnutrition AND medical
complications OR feeding issue
-Severe dehydration (Two of the
following)
--Lethargic or unconscious
--Sunken eyes
--Not able to drink or drinking poorly
--Reduced skin turgor
- Stridor in a
calm child
-SaO2 < 90% on
RA (if available)
-Chest
indrawing and
HIV positive
-Tender
swelling
behind ear
-Severe
palmar pallor
-Severe
complicated
measles
WHO [7]
Indications
for antibiotic
treatment
-Uncomplicated severe malnutrition -Cough and
tachypnea and/
or chest
indrawing after
trial of
bronchodilator
(2-12 m: RR >
50/min; ≥12 m:
RR > 40/min)
-Ear pain or
ear discharge
< 14 days
-Blood in
stool
If yes to any of the danger signs: referral and IM antibiotics
If yes to any of the antibiotic signs: oral antibiotic treatment
iCCM 2m-5y CNS Hydration/ nutrition Respiratory Other
Danger signs - Lethargic or unconscious
-h/o convulsions or currently seizing
-Vomits everything
-Unable to drink/ breastfeed
-Severe malnutrition (low MUAC or
bilateral edema)
-Chest
indrawing
-HIV positive
-Blood in
stool
WHO [40]
Indications
for antibiotic
treatment
-Cough and
tachypnea
(2-12 m: RR >
50/min; ≥12 m:
> 40/min)
If yes to any of the antibiotic signs; oral antibiotic treatment
If yes to any of the danger signs: referral and oral antibiotics
ALMANACH 2m-5y CNS Hydration/ nutrition Respiratory Other
Danger signs - Lethargic or unconscious
-h/o convulsions or currently seizing
-stiff neck
-Vomits everything
-Unable to drink/ breastfeed
-Severe wasting
-Severe dehydration
(Two of the following)
--Lethargic or unconscious
--Sunken eyes
--Not able to drink or drinking poorly
--Reduced skin turgor
-Chest
indrawing
-Stridor in a
calm child
-Cyanosis
-Tender
swelling
behind ear
-Severe pallor
-Jaundice
-Severe soft
tissue
infection
Rambaud-
Althaus et
al. [9]
Indications
for antibiotic
treatment
Cough and
RR > 50/min
Acute ear
discharge
Blood in stool
Urine dipstick
(Positive
leucocyte or
nitrite)
Abdominal
tenderness
If yes to any of the antibiotic signs; oral antibiotic treatment
If yes to any of the danger signs: referral and IM antibiotics
NICE traffic light
system
0-5y Color Activity Respiratory Circulation and
Hydration
Other NICE:
Feverish
Illness in
Children
[26]
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validation. Table 3 displays the prediction rules and guide-
lines that could be included into validation exercise. It also
details the categories of SBI that were considered for the
initial derivation or development of each rule/guideline.
Validation dataset
The full details on the demographic and clinical charac-
teristics of the study population are provided in the
original study report [2]. A SBI was identified in 16%
(162/1005) of patients in the validation dataset (Table 4).
Validation results
The diagnostic accuracy for all included prediction rules
and guidelines was low to moderate (Table 5). The
Bleeker rule, Rotterdam Fever Model (2.5% risk cutoff),
and NICE guidelines had the highest sensitivity, ranging
from 77.3 to 83.7%. However, the specificity of the
Bleeker score was only 40.8% (95% CI 36.9–44.9%), and
those of the Rotterdam Fever Model (2.5% risk cutoff), and
NICE guidelines even lower: 35.6% (95% CI 32.4–39.0%)
and 25.2% (95% CI 22.6–28.6%), respectively. IMCI
(like iCCM) had a very low sensitivity of 37.0% (95% CI
29.4–44.6%) and a moderate specificity of 70.3% (95% CI
67.1–73.4%). Compared to IMCI, ALMANACH had a
higher sensitivity of 63.3% (55.4–70.6%). However,
ALMANACH’s specificity was lower compared to IMCI
(63.2, 95% CI 59.8–66.4%). None of the scores had LRs
that would be considered helpful for ruling-in or ruling-
out SBI in low-prevalence settings (LR+ greater 5 or LR-
lower than 0.2).
Figure 2 illustrates the overlap between SBI classifica-
tion (reference) and antibiotic treatment classifications
by the score. The Bleeker score and NICE guideline
achieved the highest proportion of correct classifications
Table 2 Guidelines for management of acute febrile illnesses in childrena (Continued)
Name of
guideline
Age
Group
Clinical and laboratory features Publication
Red- high risk - Pale/mottled/
Ashen/blue
-No response to
social cues
-Appears ill to
healthcare
professional
-Does not wake or if
roused does not
stay awake
-Weak high-pitched
or continuous cry
- Grunting
- RR > 60/min
- Moderate/
severe chest
indrawing
- Reduced skin
turgor
- Age 0-3 m &
T ≥ 38 °C
- Non-
blanching
rash
- Bulging
fontanel
- Neck
stiffness
- Status
epilepticus
- Focal
neurological
signs
- Focal
seizures
Amber-
intermediate
risk
- Pallor - Not responding
normally to social
cues
- Wakes only with
prolonged
stimulation
- Decreased activity
- No smile
- Nasal flaring
- Tachypnea
(6-12m: RR >
50/min; > 12
m: > 40/min)
- SaO2≤ 95%
- Crackles
-Tachycardia(<
12 m: > 160
bpm; 12-24m:
> 150 bpm; 2-
5y: > 140 bpm)-
Dry mucous
membranes
- Poor feeding
in infants
- CRT≥ 3 s
- Reduced urine
output
- fever ≥5
days
- swelling of a
limb or joint
- non-weight
bearing
limb/not
using
extremity
- age 3-6 m,
T ≥ 39 °C
Values If yes to any of these 5 categories, each scoring 2 to 13 features
American
Academy of
Emergency
Physicians
Guidelines
3–36
m
Ill appearing Positive chest
radiography (to be
obtained if:T ≥
39 °Cand WBC > 20
K/mm3 or “clinical
evidence of lower
respiratory infection”
Positive urine
leucocyte +
nitrite (to be
obtained in
male < 1 year
and female <
2 year)
T ≥ 39 °C
And WBC > 15 K/mm3
American
Academy
of
Emergency
Physicians
[27]
Values If yes to any of these features
bpm Beats per minute, CRT Capillary refill time, CRP C-reactive protein, h/o History of, m Months, SaO2 Oxygen saturation, PCT Procalcitonin, RR Respiratory rate, T
Body temperature, Y Yes, y Years, WBC White blood cell count
aModified and appended from Verbakel et al. [33]
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(14% of the total population) but at the expense of many
unnecessary antibiotic prescriptions: 49 and 62% of
patients, respectively. IMCI, iCCM and the Thayyil score
resulted in the lowest proportion of correct classifica-
tions (6% of patients).
Figure 3 shows the missed cases of SBI according to differ-
ent classifications. Not surprisingly, IMCI, iCCM, and AAEP
missed very few pneumonia cases since the classifications
used by these guidelines were part of the outcome definition
(see Sensitivity analyses). Similarly, missed UTI cases were
fewer in scores that use urine laboratory testing. All rules
and guidelines, besides the Rotterdam model at low cutoff
and the NICE guideline, missed a large amount of pa-
tients with bacteremia (50–75% of bacteremia cases).
Sensitivity analyses
Applying the rule only to the age group for which it was
originally designed, resulted in a significantly higher
specificity for the Bleeker rule, Thayyil score, Lab Score
and AAEP guideline (Table 6). We found similar results
for relevant scores when including patients without
pneumonia or without malaria only, when compared to
the full validation dataset (Table 6). The specificity of
ALMANACH was increased when applying to patients
without UTI only. There was no significant change in
the performance of prediction rules originally derived
for children with fever without source when we com-
pared the full dataset with the dataset containing chil-
dren with fever without source only (Table 6).
Table 4 Cross table of serious bacterial infection (SBI) categories
SBI categories, % (n), N = 1005
Meningitis Pneumonia Bacteremia UTI Typhoid Cellulitis/
Abscess
Bacterial
gastroenteritis
Leptospirosis Intracellular
bacteria
Meningitis 0.2 (2) 0 0 0 0 0 0 0 0
Pneumonia 3.1 (31) 0 0 0.4 (4) 0 0 0 0
Bacteremiaa 1.7 (18) 0.4 (4) 0.4 (4) 0 0.1 (1) 0 0
UTI 5.9
(59)
0.1 (1) 0 0 0 0
Typhoid 3.7 (37) 0 0.2 (2) 0 0
Cellulitis/ Abscess 0.5 (5) 0 0 0
Bacterial
gastroenteritis
1.4 (14) 0 0
Leptospirosis 0.4 (4) 0
Intracellular bacteria 1.1 (11)
a positive blood culture for a known pathogen other than Salmonella typhi
Table 3 Prediction rules and guidelines that could be used for validation and SBI considered for each rule in the original derivation
study/ at development
Prediction
rule/guidelines
SBI categories considered
Meningitis Pneumonia Bacteremia UTI Typhoid Cellulitis/
Abscess
Bacterial
gastroenteritis
Leptospirosis Intracellular
bacteria
Other
Bleeker ✓ ✓ ✓ ✓ ✓a ✓ Osteomyelitis,
Ethmoiditis
Thayyil ✓ ✓ ✓ ✓ ✓a Any positive bacterial
culture from an
otherwise sterile site
Lab Score ✓ ✓ ✓ ✓b ✓a ✓
Rotterdam
fever modelc
✓ ✓ ✓ ✓ ✓a ✓ ✓ Osteomyelitis
IMCI ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
iCCM ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
ALMANACH ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
NICE ✓ ✓ ✓ ✓ ✓ ✓ ✓ Osteomyelitis
AAEP ✓ ✓ ✓ ✓ ✓ ✓ ✓ Osteomyelitis
aBacteremia only
bPyelonephritis was defined as positive urine culture and positive DMSA scan
cAdmission to the hospital was a pre-requisite for definition of SBI
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Discussion
In the outpatient setting in Tanzania, none of the pre-
diction rules and guidelines examined had sufficient
diagnostic accuracy to detect children with SBI. IMCI
and iCCM, which were designed to be sensitive for de-
tecting SBI in these settings, actually had very low sensi-
tivities when applied to our validation dataset. The
Bleeker score, NICE guidelines, and Rotterdam Model at
low cutoff showed the highest, though moderate, sensi-
tivity, indicating a value in ruling-out children for SBI in
low-prevalence, peripheral health care settings. However,
at the same time, they classified many children as having
a SBI, i.e. requiring antibiotic treatment. The use of such
rules or guidelines would hence require further con-
firmatory testing to avoid antibiotic over-prescription.
Rules that use a combination of clinical and laboratory
testing, the Bleeker score, Rotterdam Model, ALMA-
NACH, and AAEP guideline had better performance
compared to rules and guidelines using only clinical and
or laboratory elements. We performed several sensitivity
analyses to estimate whether differences in demographic
and ecological characteristics between the derivation and
validation population had an influence on the diagnostic
accuracy. Importantly, we did not find significant differ-
ences in the performance of the SBI scores in patients of
the targeted age group or patients without malaria only
when compared with the entire study population.
To our knowledge, this was the first comprehensive
attempt to examine the accuracy of IMCI and other pre-
diction rules and guidelines in diagnosing SBI in a trop-
ical, low-resource outpatient setting against a robust
gold standard. Besides one 1995 study in Bangladesh
that performed blood cultures and CXR [12], guidelines
developed for low-resource-settings (IMCI, iCCM,
ALMANACH) have never been validated against care-
fully established gold standards (contrary to expert opin-
ion). Overall guidance for SBI other than pneumonia
and dysentery are lacking in the current IMCI guide-
lines, which specifies only “to give antibiotic treatment if
a bacterial source of infection is identified”. But identify-
ing such bacterial infections without guidance is challen-
ging for low-level health workers. Alarmingly, the
sensitivity of IMCI was very low—IMCI was originally
designed to be very sensitive at the expense of being
specific for detection of infections requiring antibiotic
treatment. The diagnostic accuracy of ALMANACH
sought to address these challenges through adding urin-
ary dipstick testing and a clinical predictor for typhoid
[41]. Indeed, sensitivity was improved but at the cost of
a lower specificity in our dataset. Generally, very few
studies have validated outpatient prediction rules and
clinical guidelines for SBI systematically. One recent
study validated systematically four clinical prediction
rules and two national guidelines retrospectively across
datasets from primary care and emergency departments
in Europe [33]. The diagnostic accuracy of the prediction
rules and guidelines also validated in our study were
generally higher. This may be due to the fact that the
original derivation population was more similar to the
validation datasets of the European validation study.
Other studies in the African setting have evaluated
scores for SBI and death at the inpatient level. Nadjm et
al. evaluated prospectively the accuracy of WHO hos-
pital-level clinical criteria for presumptive antibiotic
treatment in detecting SBI (positive blood and/or cere-
brospinal fluid culture) among 3639 admitted children
in Tanzania [42]. The sensitivity was higher when com-
pared to IMCI in our study (67.4, 95% CI 65.9–69.0%), at a
Table 5 results of external validation of prediction rules and guidelines to rule-in and rule-out serious bacterial infection
Prediction
rule/guideline
n/Na %test
positive
% sensitivity
(95% CI)
% specificity
(95% CI)
Likelihood ratio (95% CI)
positive negative
Bleeker 126/731 62.9% 81.0 (73.0–87.4) 40.8 (36.9–44.9) 1.37 (1.23–1.52) 0.47 (0.32–0.68)
Thayyil 162/1001 5.2% 31.7 (24.7–39.4) 74.4 (71.3–77.4) 1.24 (0.96–1.60) 0.92 (0.82–1.03)
Lab Score 126/731 68.3% 70.6 (61.9–78.4) 32.2 (28.5–36.1) 1.04 (0.92–1.18) 0.91 (0.68–1.22)
Rotterdam fever model
2.5% risk 161/985 66.50% 77.3 (70.1–83.5) 35.6 (32.4–39.0) 1.21 (1.10–1.32) 0.64 (0.47–0.86)
5% risk 161/985 55.53% 69.9 (62.3–76.9) 47.3 (43.9–50.8) 1.33 (1.18–1.50) 0.64 (0.50–0.81)
15% risk 161/985 36.24% 49.7 (41.8–57.6) 66.4 (63.1–69.6) 1.48 (1.23–1.78) 0.76 (0.65–0.89)
IMCI 164/1005 30.8% 36.7 (29.4–44.6) 70.3 (67.1–73.4) 1.22 (0.97–1.55) 0.90 (0.79–1.02)
iCCM 164/1005 30.5% 36.7 (29.4–44.6) 70.7 (67.5–73.7) 1.25 (1.00–1.57) 0.89 (0.79–1.01)
ALMANACH 164/1005 44.3% 63.3 (55.4–70.6) 63.2 (59.8–66.4) 1.72 (1.48–1.99) 0.58 (0.47–0.71)
NICE 164/1005 76.0% 83.7 (77.2–89.0) 25.5 (22.6–28.6) 1.12 (1.04–1.22) 0.64 (0.44–0.92)
AAEP 164/1005 41.7% 68.1 (60.4–75.1) 63.5 (60.2–66.8) 1.87 (1.63–2.14) 0.50 (0.40–0.63)
aNumber of children with SBI out of all children included into validation. N represents the total number of children for which all variables of the prediction rule
were recorded (please also refer to Additional file 2: Table S1)
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lower specificity of 51.5% (95% CI 49.9–53.1%). Reported
sensitivities of a similar study by Berkley at al. were even
higher [43]. However, the comparison of results from these
studies with the present analysis is extremely limited by the
difference in prevalence of SBI in the inpatient versus out-
patient setting, and the restricted number of investigations
for SBI performed (blood and cerebrospinal fluid culture
only). Conroy et al. validated three scores to predict in-hos-
pital (and not outpatient) mortality among Ugandan chil-
dren with fever [44]. Through mortality is a relevant and
robust outcome, its use at the outpatient level, where death
is a rare event, is difficult.
This study has several limitations. Only a single data-
set from was available for validation, which limits the
generalizability of our findings. However, rates of
bacteremia in our study were similar to other studies
conducted at primary care level around the same time
and the dataset is likely representative of the typical
case-mix [45]. There are multiple sources of heterogen-
eity. The most obvious one is the difference in setting
for all prediction rules and two out of the four guide-
lines. Difference in bacterial pathogens, such as typhoid
and rickettsial diseases, substantially limits the applic-
ability of “Northern” guidelines to tropical settings.
Differences in recorded values between the derivation
and validation datasets is another limitation for this
analysis. Though this study used robust, predefined ref-
erence criteria with extensive microbiological testing, the
gold standards for SBI certainly remain imperfect [46].
For pneumonia end-point consolidation on CXR has
been used though it is known that only an (unknown)
percentage of consolidations are of bacterial origin, and
that viral pneumonia may produce abnormalities on
CXR as well [47]. As a result, test diagnostic accuracy
Fig. 2 Overlap of serious bacterial infection classification (blue) and antibiotic treatment classification per rule or guideline (pink). The blue circles
represent the percentage of patients with a SBI identified in the validation dataset. The pink circles illustrate the percentage of patients that
tested ‘positive’ in the dataset per the rule or guideline. The overlap represents the percentage of patients with SBI who were correctly classified
as such according to the rule
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may be biased in both directions. The diagnostic accur-
acy of all available tests for typhoid is poor [48] and
hence the typhoid classification (combination of rapid
test and blood and stool cultures), was certainly subopti-
mal. Consequently, the sensitivity of guidelines to detect
SBI may have been underestimated. Despite the compre-
hensive set of clinical and laboratory predictors in the
validation dataset, we were able to validate only four of
the nine prediction rules plus all guidelines and had to
use proxies for several predictors. For the Bleeker score,
for example, “ill-appearance” was likely underestimated
in our validation dataset since the variables “lethargy,
and very sick child” refer to a sicker child. On the other
hand, using the urine leucocyte dipstick test instead of
the urine WBC likely overestimated the presence of
UTI. We did not impute missing data as the “missing at
random assumption” could not be assumed for the valid-
ation dataset; this may have influenced our estimates of
performance for those rules that use urinary dipstick
testing where we encountered a large percentage of
missing data in the validation set.
Our findings have several implications for clinical prac-
tice and research in low-resource settings. First, the efforts
should be made to increase the sensitivity of current
screening tools for SBI. As it was intended for IMCI, clin-
ical guidelines should have high sensitivity as the access to
care in such settings is difficult, referral to higher level of
care may be delayed, and safety-netting is not always
available. Guidelines should be presented as stepwise deci-
sion algorithms, which follow the logical flow of the actual
diagnostic process [46]. This is especially true for low-re-
source settings where health care providers with limited
training benefit from clinical decision algorithms [49].
Within such algorithms, simple but sensitive clinical
criteria will be needed to quickly rule-out children with
SBI. This could then be followed by a more specific sec-
ond-step laboratory testing, such as point-of-care bio-
markers, in order to avoid unnecessary antibiotic
treatment. However, no algorithm will have perfect diag-
nostic accuracy making safety netting (follow-up) an im-
portant component of clinical care. Third, disease
management algorithms should undergo careful external
validation before implementation. Ideally, such validation
studies should be performed against clinical outcome, and
not against a microbiological reference standard only as it
is difficult to establish a valid microbiological reference
standard. This could either be achieved through compos-
ite reference standards including clinical patient follow-up
[46], or through the evaluation of decision rules through
randomized clinical trials [32].
Viral infections, such as bronchiolitis, may cause
severe disease. The guidance on supportive measures
for viral infections by a clinical algorithm designed for
the low-resource outpatient setting may be become
equally important with declining prevalence of SBI.
ALMANACH, for example, achieved better clinical
Fig. 3 Missed cases of serious bacterial infections (SBI)
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outcome in a validation study against routine care in
Tanzania [50].
Conclusions
None of the examined prediction rules and guidelines had
sufficient diagnostic accuracy to detect children with SBI
in a tropical, low-resource setting. IMCI and iCCM, which
were designed to be sensitive for detecting SBI in these
settings, actually had very low sensitivities when applied to
our validation dataset. Some prediction rules and guide-
lines had higher sensitivity and hence showed promise to
rule-out SBI in our dataset. However, they also classified a
larger number of patients as having a SBI, calling for
additional second-stage testing, such as point-of care
inflammatory markers, and tests for severity such as oxim-
etry and hemoglobin. New clinical algorithms should
undergo careful external validation studies against clinical
outcome before implementation in routine care.
Table 6 Results of sensitivity analyses
Prediction
rule/guideline
n/N %test
positive
% sensitivity
(95% CI)
% specificity
(95% CI)
Likelihood ratio (95% CI)
positive negative
Derivation age-group only
Bleeker 88/507 46.5% 72.7 (62.2–81.7) 58.9 (54.1–63.7) 1.77 (1.49–2.10) 0.46 (0.33–0.66)
Thayyil 124/777 5.4% 11.3 (6.3–18.2) 95.7 (93.9–97.1) 2.63 (1.43–4.86) 0.93 (0.87–0.99)
Lab Score 88/507 54.2% 58.0 (47.0–68.4) 46.5 (41.7–51.4) 1.08 (0.89–1.32) 0.90 (0.69–1.18)
Rotterdam fever model
2.5% risk 161/985 66.50% 77.6 (70.4–83.8) 35.7 (32.4–39.1) 1.21 (1.10–1.33) 0.63 (0.46–0.85)
5% risk 161/985 55.53% 70.2 (62.5–77.1) 47.3 (43.9–50.8) 1.33 (1.18–1.50) 0.63 (0.49–0.81)
15% risk 161/985 36.24% 49.7 (41.7–57.7) 66.4 (63.0–69.6) 1.48 (1.23–1.77) 0.76 (0.65–0.89)
IMCI 154/941 26.1% 31.8 (24.6–39.8) 70.0 (71.8–78.0) 1.27 (0.98–1.65) 0.91 (0.81–1.02)
iCCM 154/941 25.8% 31.8 (24.6–39.8) 75.3 (72.2–78.3) 1.29 (0.99–1.68) 0.90 (0.81–1.02)
ALMANACH 154/941 40.5% 64.9 (56.8–72.4) 64.3 (60.8–67.6) 1.82 (1.57–2.11) 0.55 (0.44–0.68)
NICE 154/941 74.4% 82.5 (75.5–88.1) 27.2 (24.1–30.4) 1.13 (1.04–1.23) 0.64 (0.45–0.93)
AAEP 122/756 22.5% 58.2 (48.9–67.1) 84.4 (81.3–87.1) 3.73 (2.95–4.72) 0.50 (0.40–0.61)
Patients without pneumonia only
IMCI 133/974 28.7% 21.8 (15.1–29.8) 70.2 (66.9–73.2) 0.73 (0.52–1.02) 1.11 (1.01–1.23)
iCCM 133/974 28.4% 21.8 (15.1–29.8) 70.5 (67.3–73.6) 0.74 (0.53–1.04) 1.11 (1.00–1.23)
ALMANACH 133/974 43.5% 66.9 (58.2–74.8) 60.2 (56.8–63.5) 1.68 (1.45–1.94) 0.55 (0.43–0.70)
AAEP 133/841 39.9% 62.4 (53.6–70.7) 63.6 (60.3–66.9) 1.72 (1.46–2.01) 0.59 (0.47–0.74)
Patients without UTI only
Bleeker 67/672 60.2% 70.1 (57.7–80.7) 40.8 (36.9–44.9) 1.19 (1.00–1.40) 0.73 (0.50–1.07)
Lab Score 67/672 67.9% 68.7 (56.2–79.4) 32.2 (28.5–36.1) 1.01 (0.85–1.20) 0.97(0.67–1.41)
ALMANACH 107/946 31.8% 48.6 (38.8–58.5) 70.3 (67.1–73.4) 1.64 (1.31–2.04) 0.73 (0.60–0.88)
AAEP 107/946 39.4% 62.6 (52.7–71.8) 63.5 (60.2–66.8) 1.72 (1.45–2.04) 0.59 (0.46–0.76)
Patients with negative malaria test only
Bleeker 119/643 60.4% 79.8 (71.5–86.6) 43.9 (39.6–48.3) 1.42 (1.26–1.60) 0.46 (0.32–0.67)
Thayyil 153/897 24.0% 31.4 (24.1–39.4) 77.6 (74.4–80.5) 1.40 (1.07–1.83) 0.88 (0.79–0.99)
Lab Score 119/642 65.4% 68.9 (59.8–77.1) 35.4 (31.3–39.6) 1.07 (0.93–1.22) 0.88 (0.66–1.18)
Rotterdam fever model
2.5% risk 152/881 62.9% 76.3 (68.7–82.8) 39.9 (36.3–43.6) 1.27 (1.14–1.41) 0.59 (0.44–0.80)
5% risk 152/881 51.1% 68.4 (60.4–75.7) 52.5 (48.8–56.2) 1.44 (1.26–1.65) 0.60 (0.47–0.77)
15% risk 152/881 32.1% 48.0 (39.9–56.3) 71.2 (67.8–74.5) 1.67 (1.36–2.04) 0.73 (0.62–0.86)
Patients with fever without source only for scores that were derived in children with fever without source
Bleeker 73/315 69.8% 80.8 (69.9–89.1) 33.5 (27.6–39.8) 1.21 (1.05–1.40) 0.57 (0.35–0.95)
Thayyil 77/367 30.8% 27.3 (17.7–38.6) 68.3 (62.6–73.6) 0.86 (0.58–1.28) 1.07 (0.91–1.25)
Lab Score 73/314 72.2% 71.2 (59.4–81.2) 27.4 (21.9–33.5) 0.98 (0.83–1.16) 1.05 (0.69–1.59)
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